July 8th: KOL Webinar for Pulmonary Arterial Hypertension

Corsair Pharma, Inc., a private biopharmaceutical company developing a transdermal treprostinil prodrug, today announced it will host a Key Opinion Leader (KOL) webinar to discuss the current treatment landscape for Pulmonary Arterial Hypertension (PAH) on Thursday, July 8th, at 10:30 a.m. ET.

More details here. To register for the webinar and listen to the replay, click here.